Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280033 · ClinicalTrials.gov registry record · Phase 1
H5 Adult - Chiron Study of Bird Flu Vaccine
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 394
- Enrollment target
NCT00280033: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00280033 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 394 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (557% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00280033, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 394 participants
- Enrollment target
Study Summary
This study is will gather critical information on the safety, tolerability, and the immunogenicity (capability of causing an immune response) of A/H5N1 (Bird flu) virus vaccine in healthy adults. Up to 400 healthy adults, aged 18 to 64, will participate. Each subject will participate for about 7 months and will be randomly placed in one of several different study groups receiving a different dose of vaccine or placebo. All subjects will receive two injections of their assigned study product, about 28 days apart, in the muscle. Subjects will keep a journal of their temperature and any adverse effects between study visits. A small amount of blood will also be drawn before the first injection, 7 days after each injection, 1 month after the first injection, and 1 and 6 months after the second injection.
Interventions
- DRUG Placebo
- BIOLOGICAL Aluminum hydroxide
- BIOLOGICAL MF-59
- BIOLOGICAL Inactivated Influenza A/H5N1 Vaccine (Chiron)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
What the finished NCT00280033 record still lists
NCT00280033 is an interventional study that assigns participants to a tested intervention. The registered 394 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (557% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00280033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00280033 about?
NCT00280033 is a clinical study titled "H5 Adult - Chiron Study of Bird Flu Vaccine". This study is will gather critical information on the safety, tolerability, and the immunogenicity (capability of causing an immune response) of A/H5N1 (Bird flu) virus vaccine in healthy adults. Up to 400 healthy adults, aged 18 to 64, will participate. Each subject will participate for about 7 mon...
What is the current status of trial NCT00280033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 394 participants. The study started on 2006-02. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00280033?
The interventions under investigation include: Placebo (DRUG), Aluminum hydroxide (BIOLOGICAL), MF-59 (BIOLOGICAL), Inactivated Influenza A/H5N1 Vaccine (Chiron) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00280033?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00280033's enrollment target sits among peer trials
394 77th of 2000 higher than 1,924 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia